Expression of SLC22A18 regulates oxaliplatin resistance by modulating the ERK pathway in colorectal cancer.

Although oxaliplatin-based chemotherapy is the current standard adjuvant therapy for colorectal cancer (CRC), the molecular mechanisms underlying oxaliplatin resistance remain unclear. Here, we examined the molecular mechanisms underlying SLC22A18-associated oxaliplatin resistance and strategies for overcoming oxaliplatin resistance. We evaluated the association between SLC22A18 and prognosis in 337 patients with CRC and its functional significance and studied the mechanisms through which SLC22A18 affects oxaliplatin resistance development in CRC cells, using CRC cell lines and patient-derived cells (PDCs). SLC22A18 downregulation was positively correlated with worse survival in patients with CRC. Low SLC22A18-expressing cells showed relatively lower sensitivity to oxaliplatin than high SLC22A18-expressing cells. In addition, ERK activation was found to be involved in the mechanisms underlying SLC22A18-related oxaliplatin resistance. To confirm ERK pathway dependence, we used an ERK inhibitor and found that combined treatment with oxaliplatin and the ERK inhibitor overcame oxaliplatin resistance in the low SLC22A18-expressing cells. Ex vivo approaches using PDC confirmed the correlation between SLC22A18 expression and oxaliplatin resistance. Results of the in vivo study showed that SLC22A18 expression regulated oxaliplatin efficacy, and that combined treatment with an ERK inhibitor could be a useful therapeutic strategy when SLC22A18 is downregulated. Together, our findings indicate that SLC22A18 could serve as a biomarker for the prediction of oxaliplatin resistance. In cases of oxaliplatin resistance due to low SLC22A18 expression, resistance can be overcome by combined treatment with an ERK inhibitor.

[1]  K. Ghaedi,et al.  Signaling pathways involved in colorectal cancer progression , 2019, Cell & Bioscience.

[2]  O. Fiehn,et al.  Human-like hyperplastic prostate with low ZIP1 induced solely by Zn deficiency in rats , 2018, Proceedings of the National Academy of Sciences.

[3]  Charles H. Yoon,et al.  Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras/MEK/ERK and PI3K/Akt/mTOR pathways , 2018, Carcinogenesis.

[4]  G. Scagliotti,et al.  A systematic review of the safety profile of the different combinations of fluoropyrimidines and oxaliplatin in the treatment of colorectal cancer patients. , 2018, Critical reviews in oncology/hematology.

[5]  D. Xie,et al.  Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway , 2017, Molecular Cancer.

[6]  Jun Yu,et al.  SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate. , 2016, Gastroenterology.

[7]  M. Kanda,et al.  Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer , 2015, BMC Cancer.

[8]  Y. Cho,et al.  Characterization of SLC22A18 as a tumor suppressor and novel biomarker in colorectal cancer , 2015, Oncotarget.

[9]  Z. Bi,et al.  HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway , 2015, Cancer biology & therapy.

[10]  Qing Li,et al.  Role of solute carriers in response to anticancer drugs , 2014, Molecular and Cellular Therapies.

[11]  A. Jemal,et al.  Annual Report to the Nation on the status of cancer, 1975‐2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer , 2014, Cancer.

[12]  Q. She,et al.  ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer , 2013, Oncogene.

[13]  A. Hinke,et al.  Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  D. Feng,et al.  Effect of 5-Aza-2'-deoxycytidine on SLC22A18 in glioma U251 cells. , 2011, Molecular medicine reports.

[15]  D. Feng,et al.  Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma , 2011, Journal of Translational Medicine.

[16]  Amine Sadok,et al.  Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines , 2009, British journal of pharmacology.

[17]  R. Busch,et al.  Comparison of personality traits in patients with frontal and temporal lobe epilepsies , 2009, Epilepsy & Behavior.

[18]  C. Der,et al.  KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer , 2009, Molecular Cancer Therapeutics.

[19]  M. Hung,et al.  Induction of Akt activity by chemotherapy confers acquired resistance. , 2009, Journal of the Formosan Medical Association = Taiwan yi zhi.

[20]  K. Gopinath,et al.  Characterization of the human SLC22A18 gene promoter and its regulation by the transcription factor Sp1. , 2009, Gene.

[21]  K. Leelawat,et al.  Cancer Cell International Inhibition of Pi3k Increases Oxaliplatin Sensitivity in Cholangiocarcinoma Cells , 2022 .

[22]  D. Nebert,et al.  Analysis and update of the human solute carrier (SLC) gene superfamily , 2009, Human Genomics.

[23]  Gang Meng,et al.  Changes in genomic imprinting and gene expression associated with transformation in a model of human osteosarcoma. , 2008, Experimental and molecular pathology.

[24]  B. Sarg,et al.  Cetuximab inhibits thymidylate synthase in colorectal cells expressing epidermal growth factor receptor , 2008, Proteomics. Clinical applications.

[25]  W. Scheithauer,et al.  Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T. Hamilton,et al.  Platinum Resistance: The Role of DNA Repair Pathways , 2008, Clinical Cancer Research.

[27]  R. Goldberg.  Intensive surveillance after stage II or III colorectal cancer: is it worth it? , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  W. Sadee,et al.  Growth factor signaling and resistance to cancer chemotherapy. , 2004, Current topics in medicinal chemistry.

[29]  Daniel J Sargent,et al.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  C. Plass,et al.  SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S. Hector,et al.  In vitro studies on the mechanisms of oxaliplatin resistance , 2001, Cancer Chemotherapy and Pharmacology.

[32]  S. Suster,et al.  Identification of a colon mucosa gene that is down-regulated in colon adenomas and adenocarcinomas. , 1993, Proceedings of the National Academy of Sciences of the United States of America.